Botulinum toxin A for the treatment of cervical dystonia.

Abstract

Idiopathic cervical dystonia (ICD) is the most common adult-onset focal dystonia. It is characterised by relatively sustained, involuntary contractions of neck muscles. Injections of botulinum toxin (BTX)-A are safe and effective for the treatment of ICD, and have substantially improved its treatment. BTX-A is manufactured by Allergan Pharmaceuticals in the US and Ireland, and is distributed as Botox. In Europe, BTX-A is manufactured and distributed by Ipsen Pharmaceuticals as Dysport. Success rates for BTX-A injections for ICD ranges 64-90%, with 76-93% of injected patients experiencing pain reduction. Side effects are generally mild and include dysphagia and neck weakness.

• Authors: Theresa A Zesiewicz, William Stamey, Kelly L Sullivan, Robert A Hauser
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 5 Issue 9 Pg. 2017-24 (Sep 2004) ISSN: 1744-7666 [Electronic] England
• PMID: 15330738 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies
• Botulinum Toxins, Type A

Topics

• Adult
• Antibodies
• Botulinum Toxins, Type A (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Controlled Clinical Trials as Topic
• Humans
• Torticollis (drug therapy)